Blake Insomnia Therapeutics, Inc. (OTCMKTS:BKIT) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure

On September 6, 2017, we made an investor presentation that included the slides furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

SECTION 9 – Financial Statements and Exhibits

99.1 Investor presentation, dated September 6, 2017

Blake Insomnia Therapeutics, Inc. Exhibit
EX-99.1 2 ex99_1.htm 1 Blake Insomnia Therapeutics                             2 Forward L ooking Statements This presentation contains forward – looking statements made within the meaning of the Private Securities Litigation Reform Act of 1995 by Blake Insomnia Therapeutics,…
To view the full exhibit click here

About Blake Insomnia Therapeutics, Inc. (OTCMKTS:BKIT)

Blake Insomnia Therapeutics, Inc. is a development-stage pharmaceutical company. The Company operates as a provider of insomnia remedy. The Company is focused on developing its business plan for an insomnia medication known as Zleepax. Zleepax is a sleep aid with beta blockers as an active agent. As of August 31, 2016, the Company had no revenues.

Blake Insomnia Therapeutics, Inc. (OTCMKTS:BKIT) Recent Trading Information

Blake Insomnia Therapeutics, Inc. (OTCMKTS:BKIT) closed its last trading session down -0.0008 at 0.0682 with 7,752 shares trading hands.